From: CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110
Tumor cell line | Cancer type | CD13 status | IC50 (μg/mL) | GSD |
---|---|---|---|---|
HT1080 | Fibrosarcoma | Positive | 0.17 | 1.32 |
NB-4 | Leukemia | Positive | 0.10 | 3.5 |
U-937 | Lymphoma | Positive | 0.14 | 3.3 |
RPMI 8226 | Myeloma | Negative | > 1.0 | - |
Raji | Lymphoma | Negative | > 1.0 | - |